Unrefined Salmon Oil as Dietary Supplement in Adult Asthmatics
Asthma
About this trial
This is an interventional prevention trial for Asthma focused on measuring anti-inflammatory, salmon oil, marine-derived Omega 3, Dyspnea; Asthmatic, Airway Obstruction, Pulmonary Disease, Inflammation Lungs
Eligibility Criteria
Inclusion Criteria:
- Asthma Global Initiative for Asthma (GINA) treatment grade 2-4 (only standard care of inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA), no additional treatment except as-needed short--acting beta2-agonist (SABA)
- ACQ-5 score ≥0.75
- Diagnosed with asthma by medical doctor (general practitioner or pulmonary spesialist)
- Eosinophils ≥ 150 µL
- Speaks fluent Norwegian.
- For female in fertile age, use of contraception or other indication for non-pregnancy.
- Signed informed consent and expected cooperation of the participants for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations.
Exclusion Criteria:
- Treatment with oral corticosteroid <1 month prior to baseline visit
- Treatment with any biological medication, <6 months prior to baseline visit
- Oral/intravenous antibiotics < 3 months prior to baseline visit
- Consumption of fish oil (liquid, capsule, powder) as an oral supplement < 1-month prior baseline visit
- Known fish or shellfish allergy
- Pregnancy and breast feeding
- Participant in a confounding study
- Inflammatory bowel disease (Chron, ulcerative colitis (UC), microscopic colitis), celiac disease, or any chronic disease that possibly affects intestinal absorption and morbidity
- In case of severe cognitive impairment where the participants are not able to fulfill the study
- Not willing to participate
- Any reason why, in the opinion of the investigator, the participant cannot participate.
Sites / Locations
- Hofseth Biocare ASARecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Best Standard of Care + CARDIO®
Best Standard of Care + Placebo
6 gram/day ( 1000 mg per capsule) of unrefined salmon oil, duration of 20 weeks. CARDIO® capsule contains 1000 mg of full spectrum of omega fatty acids, including 21 different fatty acids, with a minimum of 270 mg polyunsaturated fatty acids (PUFA) and10 mg lipopeptides
6 gram/day (1000 mg per capsule) of natural oil, duration of 20 weeks. The placebo is a medium-chain triglyceride (MCT), with triglyceride from natural fatty acid, mainly caprylic- and capric acid.